Jeevan Scientific Technology Limited , a company specializing in clinical research and data management services, has reported a net loss for the quarter and half year ended September 30, according to its recently released unaudited financial results.

Financial Performance

The company's consolidated financial statements reveal a significant downturn in profitability compared to the previous fiscal year. For the half year ended September 30, Jeevan Scientific Technology reported a consolidated net loss before tax of ₹369.90 lakhs, a stark contrast to the profit of ₹5.07 lakhs recorded for the year ended March 31.

On a standalone basis, the company's performance showed a similar trend:

Operational Highlights

Despite the challenging financial results, the company has maintained its operational activities. The cash flow statement indicates some positive movements:

• Net cash from operating activities stood at ₹53.76 lakhs for the half year ended September 30.
• The company saw an increase in cash and cash equivalents, rising from ₹20.59 lakhs at the beginning of the period to ₹77.42 lakhs by the end of September.

Balance Sheet Overview

As of September 30, Jeevan Scientific Technology's consolidated balance sheet showed:

• Total assets of ₹8,380.67 lakhs, up from ₹7,825.05 lakhs as of March 31.
• Total equity (including non-controlling interest) decreased to ₹4,722.01 lakhs from ₹5,007.12 lakhs.
• Current liabilities increased significantly to ₹7,345.27 lakhs from ₹1,207.05 lakhs, indicating a substantial rise in short-term obligations.

Subsidiary Performance

The company's subsidiary, Nayas Laboratories Private Limited, contributed positively to the group's results:

• Total revenues of ₹194.18 lakhs for the quarter ended September 30.
• Net profit after tax of ₹9.50 lakhs for the same quarter.

Auditor's Review

The independent auditor, Pavuluri & Co., conducted a review of the financial results. They stated that nothing has come to their attention that causes them to believe that the financial statements do not present a true and fair view in accordance with applicable accounting standards and other recognized accounting practices and policies.

Looking Ahead

While the company faces challenges in the current financial landscape, the increase in cash and cash equivalents and the positive contribution from its subsidiary may provide some stability. However, the significant rise in current liabilities and the overall net loss position suggest that Jeevan Scientific Technology may need to focus on cost management and revenue growth strategies in the coming quarters to improve its financial health.

Jeevan Scientific Technology Limited recently announced the successful completion of a Remote Interactive Evaluation (RIE) conducted by the United States Food and Drug Administration (US FDA). The evaluation, which took place from October 17, 2025 to November 6, 2025, focused on the company's Clinical Pharmacology facility.

Evaluation Scope and Outcome

The US FDA's evaluation encompassed several key areas:

• BA/BE studies
• Operations
• Systems
• Procedures

Notably, the RIE concluded with no critical observations, marking a significant achievement for Jeevan Scientific Technology.

Implications for the Company

The successful completion of this evaluation without any critical observations is a positive development for Jeevan Scientific Technology. It demonstrates the company's commitment to maintaining high standards in its clinical pharmacology operations and adherence to regulatory requirements.

This outcome may potentially:

• Enhance the company's credibility in the pharmaceutical research sector
• Strengthen its position for future collaborations or contracts
• Provide reassurance to stakeholders about the quality of the company's operations

It's important to note that this evaluation is a routine part of regulatory oversight in the pharmaceutical industry. The company will likely continue to be subject to periodic evaluations to ensure ongoing compliance with FDA standards.

Stakeholders may view this development as part of Jeevan Scientific Technology's ongoing efforts to maintain regulatory compliance and operational excellence in its field of clinical pharmacology research.